Table 2.

Clinicopathologic characteristics by BRAF and NRAS mutational status among melanoma cases (N = 214)

CharacteristicBRAF+ (n = 92)NRAS+ (n = 29)Wild-type (n = 93)BRAF+ vs wild-type, OR* (95% CI)NRAS+ vs wild-type, OR* (95% CI)
Age at diagnosis (y)
    Mean ± SD, y47.3 ± 14.162.1 ± 12.853.9 ± 17.9
    P < 0.001
    Per 10 y0.8 (0.6-0.9)1.3 (1.0-1.7)
Gender, n (%)
    Male48 (52)17 (59)52 (56)1.01.0
    Female44 (48)12 (41)41 (44)1.0 (0.5-1.8)1.0 (0.4-2.5)
Histologic subtype, n (%)
    SSM79 (86)23 (79)67 (72)1.01.0
    NM5 (5)3 (10)2 (2)3.3 (0.6-18.2)2.6 (0.4-17.9)
    LMM5 (5)2 (7)15 (16)0.4 (0.1-1.3)0.2 (0.4-1.1)
    ALM/other3 (3)1 (4)9 (10)0.3 (0.1-1.1)0.3 (0.0-2.5)
Breslow thickness (mm), n (%)
    <0.7542 (46)12 (41)66 (71)1.01.0
    ≥0.7550 (54)17 (59)27 (29)3.2 (1.7-5.9)3.2 (1.3-7.7)
  • Abbreviations: BRAF+, BRAF-mutant; NRAS+, NRAS-mutant melanoma; Wild-type, melanoma negative for BRAF and NRAS mutations; SSM, superficial spreading melanoma; NM, nodular melanoma.

  • * OR values for gender, histologic subtype, and Breslow thickness are adjusted for age as a continuous variable.

  • Two-sided ANOVA test for comparison of mean ages across BRAF+, NRAS+, and wild-type cases.

  • This category includes two ALMs that were negative for BRAF and NRAS mutations and other melanomas that were nevoid, spitzoid, and unclassifiable.